The efficacy and safety of vildagliptin in patients with type 2 diabetes: A meta-analysis of randomized clinical trials

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 4, 2012, Pages 386-398

  Cai, L ^a   Cai, Y ^a   Lu, Z J ^b   Zhang, Y ^c   Liu, P ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Beidaihe Sanatorium in Beijing Military Area ^*  (China)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

diabetes; dipeptidyl peptidase 4; efficacy; meta analysis; safety; vildagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLYCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSIDASE INHIBITOR; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

BODY WEIGHT; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FASTING PLASMA GLUCOSE; FATIGUE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION; LOW DRUG DOSE; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; SINUSITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ADAMANTANE; ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; NITRILES; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84863457464     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01323.x     Document Type: Review

References (49)

1. Fakhoury WKH, Lereun C, Wright D,. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology, 2010; 86: 44-57.
2. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008; 358: 2560-2572. (Pubitemid 351831357)
3. Control G, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009; 52: 2288-2298.
4. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 2009; 373: 1765-1772.
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care, 2009; 32: 193-203.
6. Gerich J,. Dpp-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract, 2010; 90: 131-140.
7. Todd JF, Bloom SR,. Incretins and other peptides in the treatment of diabetes. Diabet Med, 2007; 24: 223-232.
8. Neumiller JJ, Wood L, Campbell RK,. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy, 2010; 30: 463-484.
9. Amori RE, Lau J, Pittas AG,. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, 2007; 298: 194-206. (Pubitemid 47057766)
10. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL,. Dipeptidyl peptidase-4 (dpp-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (Online), 2008; Issue 2: CD006739.
11. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess, 2010; 14: 3-247.
12. Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract, 2010; 89: 216-223.
13. Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the galiant trial-a primary care, type 2 diabetes study. Diabetes Obes Metab, 2009; 11: 978-986.
14. Bolli G, Dotta F, Colin L, Minic B, Goodman M,. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab, 2009; 11: 589-595.
15. Bosi E, Dotta F, Jia Y, Goodman M,. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab, 2009; 11: 506-515.
16. Goke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res, 2008; 40: 892-895.
17. Schweizer A, Dejager S, Bosi E,. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab, 2009; 11: 804-812.
18. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. Glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab, 2009; 11: 157-166.
19. Filozof C, Gautier JF,. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med, 2010; 27: 318-326.
20. Foley JE, Sreenan S,. Efficacy and safety comparison between the dpp-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res, 2009; 41: 905-909.
21. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab, 2010; 12: 780-789.
22. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab, 2010; 12: 700-708.
23. Ahren B, Gomis R, Standl E, Mills D, Schweizer A,. Twelve- and 52-week efficacy of the dipeptidyl peptidase iv inhibitor laf237 in metformin-treated patients with type 2 diabetes. Diabetes Care, 2004; 27: 2874-2880. (Pubitemid 39565052)
24. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ,. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care, 2007; 30: 890-895. (Pubitemid 46556583)
25. Dejager S, Razac S, Foley JE, Schweizer A,. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res, 2007; 39: 218-223. (Pubitemid 46580622)
26. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S,. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab, 2007; 9: 166-174. (Pubitemid 46206560)
27. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab, 2008; 10: 1047-1056.
28. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H,. Vildagliptin dose-dependently improves glycemic control in japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract, 2009; 83: 233-240.
29. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S,. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract, 2007; 76: 132-138. (Pubitemid 46240373)
30. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D,. Twelve-week monotherapy with the dpp-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res, 2006; 38: 423-428. (Pubitemid 44047965)
31. Ristic S, Byiers S, Foley J, Holmes D,. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (laf237) dose response. Diabetes Obes Metab, 2005; 7: 692-698. (Pubitemid 41601073)
32. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab, 2008; 10: 675-682. (Pubitemid 352044298)
33. Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab, 2008; 10: 1114-1124.
34. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S,. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia, 2007; 50: 1148-1155. (Pubitemid 46701545)
35. Goodman M, Thurston H, Penman J,. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res, 2009; 41: 368-373.
36. Bolli G, Dotta F, Rochotte E, Cohen SE,. Efficacy and tolerability of vildagliptin vs. Pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab, 2008; 10: 82-90. (Pubitemid 350302434)
37. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A,. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care, 2007; 30: 217-223. (Pubitemid 46198322)
38. Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab, 2007; 9: 175-185. (Pubitemid 46206561)
39. Rosenstock J, Niggli M, Maldonado-Lutomirsky M,. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab, 2009; 11: 571-578.
40. Schweizer A, Couturier A, Foley JE, Dejager S,. Comparison between vildagliptin and metformin to sustain reductions in hba(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med, 2007; 24: 955-961. (Pubitemid 47301637)
41. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med, 2008; 25: 435-441. (Pubitemid 351490110)
42. Foley JE, Jordan J,. Weight neutrality with the dpp-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag, 2010; 6: 541-548.
43. Ahren B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care, 2010; 33: 730-732.
44. Ahren B, Foley JE,. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract, 2008; 62 (Suppl. 159): 8-14. (Pubitemid 351229609)
45. Pratley RE,. Expanding treatment options for type 2 diabetes: the old and the new. Diabetes Educ, 2009; 35 (Suppl. 1): 4S-11S.
46. Monami M, Iacomelli I, Marchionni N, Mannucci E,. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis, 2010; 20: 224-235.
47. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med, 2010; 363: 1410-1418.
48. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W,. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab, 2010; 12: 485-494.
49. Scheen AJ,. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet, 2010; 49: 573-588.